Navigation Links
Circassia Appoints Stewart Sharpe as Vice President Commercial Operations

OXFORD, England, September 18, 2012 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Stewart Sharpe to the newly-created position of Vice President, Commercial Operations.  Mr Sharpe, who has extensive experience of leading multinational product launches, will lead Circassia's preparations to commercialise its lead allergy programme.  Circassia plans to begin phase III testing of its lead ToleroMune® allergy treatment in Q4 2012.  

Stewart Sharpe brings 25 years of commercial and marketing experience to Circassia.  Most recently he was Head of Commercial & Business Development at Astellas Pharma's subsidiary OSI / Prosidion. Previously, he held senior leadership roles at Takeda, Johnson & Johnson, Novartis, Roche and Glaxo Wellcome.  During his career he has led the commercial activities for a number of new products, including the global launch of Xolair® for Novartis.  He also has wide experience of establishing highly performing teams and has a proven record of developing and implementing successful marketing strategies in several therapeutic areas, including respiratory medicine. Mr Sharpe is a Member of the Board of the Oxford Biosciences Network, a Member of the UK Biotechnology Industry Association and a Member of the Chartered Institute of Marketing.

Commenting on the appointment, Steve Harris, Circassia's CEO, said, "I am delighted to welcome Stewart to Circassia at this exciting time in the company's development. We believe our ToleroMune® technology has the potential to revolutionise allergy treatment, and as we move our lead programme into the final phase of development it is the ideal time to ramp up the extensive commercial preparations required for the successful international launch of our first product. Stewart brings to Circassia the senior-level experienceand track record of achievementneeded to help us achieve this ambitious goal, and we look forward to him leading ourcommercial preparations as we progress our novel cat allergy treatment to the marketplace."

About Circassia's ToleroMune® allergy treatments

Circassia is developing a range of allergy treatments based on its proprietary ToleroMune® technology.  This uses small sections of allergens (epitopes) to generate regulatory T cells that suppress allergic responses and create immune tolerance in patients.  The company has successfully completed a number of phase II studies with its cat, house dust mite, ragweed and grass allergy therapies.  Clinical results show that short courses of Circassia's allergy treatments can greatly reduce patients' allergic responses, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated.  As a result, the treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  More than 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is valued at approximately $12 billion per year.

About Circassia

Circassia was founded in 2006 by a team of highly experienced biotechnology scientists and entrepreneurs, and is chaired by the former Chairman of GlaxoSmithKline, Sir Richard Sykes.  The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada.  Circassia's ToleroMune technology was developed originally by scientists at Imperial College, London. Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.

Steve Harris
Tel: +44(0)1865-784574

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241

SOURCE Circassia Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Appoints Dr Brett Haumann as Chief Medical Officer
2. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
3. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
4. Nephros Appoints John C. Houghton as President and Chief Executive Officer
5. Elsevier Appoints New President of Elsevier CPM Resource Center
6. GenWay Biotech Appoints New Vice President of Custom/OEM
7. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
8. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
11. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):